Proposing the isoform-specific inhibitors of Class I PI3Ks for therapeutic applicates toward breast cancer tumours with PI3K-dependence, melanoma, non-Hodgkin lymphoma, as well as additional cancer types [59,63,191,192,193]. Here, PIK3CA is linked to neoplasm.